The Vascular Niche for Adult Cardiac Progenitor Cells.
Por:
Herrero D, Albericio G, Higuera M, Herranz-López M, García-Brenes MA, Cordero A, Roche E, Sepúlveda P, Mora C and Bernad A
Publicada:
29 abr 2022
Ahead of Print:
29 abr 2022
Resumen:
Research on cardiac progenitor cell populations has generated expectations about their potential for cardiac regeneration capacity after acute myocardial infarction and during physiological aging; however, the endogenous capacity of the adult mammalian heart is limited. The modest efficacy of exogenous cell-based treatments can guide the development of new approaches that, alone or in combination, can be applied to boost clinical efficacy. The identification and manipulation of the adult stem cell environment, termed niche, will be critical for providing new evidence on adult stem cell populations and improving stem-cell-based therapies. Here, we review and discuss the state of our understanding of the interaction of adult cardiac progenitor cells with other cardiac cell populations, with a focus on the description of the B-CPC progenitor population (Bmi1+ cardiac progenitor cell), which is a strong candidate progenitor for all main cardiac cell lineages, both in the steady state and after cardiac damage. The set of all interactions should be able to define the vascular cardiac stem cell niche, which is associated with low oxidative stress domains in vasculature, and whose manipulation would offer new hope in the cardiac regeneration field.
Filiaciones:
Herrero D:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
Albericio G:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
Higuera M:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
Herranz-López M:
Institute of Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universitas Miguel Hernández (UMH), 03202 Elche, Spain
García-Brenes MA:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
Cordero A:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
:
Institute of Bioengineering and Department of Applied Biology-Nutrition, Miguel Hernández University, 03202 Elche, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), 03010 Alicante, Spain
Sepúlveda P:
Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, Avda, Fernando Abril Martorell 106, 46026 Valencia, Spain
Mora C:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
Bernad A:
Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
gold, Green Published
FULL TEXT
 |
Published Version |
|
| No Accesible |
|